Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 23 (BNIP3P23) is a processed pseudogene located on human chromosome 19 (region 19p12). As a pseudogene, it does not encode a functional protein. BNIP3P23 has sequence similarity to the protein-coding gene BNIP3, a member of the BCL2 family involved in apoptosis and autophagy, but BNIP3P23 itself has no known biological role or clinical relevance. It is sometimes referenced as a genetic locus in genomic databases due to its sequence similarity to functional genes, but it is not a therapeutic target and has no direct implications in disease, drug response, or biology. The functional paralog, BNIP3 (BCL2 interacting protein 3), is a well-characterized apoptosis regulator and is considered a target of interest in cancer, ischemia, and other diseases, but BNIP3P23 is not.
Not applicable; no drugs or mechanisms of action relevant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 23 (BNIP3P23).